Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer by Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara

Get full text

PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study by Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu

Get full text

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab by Shota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, Shigehiro Koganemaru, Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, Toshio Kuronita, Brian Elenbaas, Pamela Wahra, Hong Zhang, Lindsey Crowley, Molly H. Jenkins, Anderson Clark, Takashi Kojima

Get full text

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicent... by Toshihiko Doi, David Tai, Dong-Wan Kim, F Stephen Hodi, Sofie Wilgenhof, Catherine Sabatos-Peyton, Giuseppe Curigliano, Chia-Chi Lin, Armando Santoro, Alexandros Xyrafas, Nicolas Mach, Sebastian Szpakowski, Shripad Chitnis, Sabine Gutzwiller, Alessandro Pastore

Get full text

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency by Shinji Kohsaka, Shigehiro Yagishita, Yukina Shirai, Yusuke Matsuno, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Masachika Ikegami, Rina Kitada, Ken-ichi Yoshioka, Kohta Toshimitsu, Kimiyo Tabata, Akira Yokoi, Toshihiko Doi, Noboru Yamamoto, Takashi Owa, Akinobu Hamada, Hiroyuki Mano

Get full text

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

Get full text